FDA hits Hong Kong OTC drugmaker with warning letter

FDA sign
The FDA issued a warning letter to Hong Kong OTC drugmaker Luen Wah Medicine. (FDA)

The FDA issued a warning letter to Hong Kong-based over-the-counter drugmaker Luen Wah Medicine, citing the company for not testing the identity and strength of each active ingredient in its products.

The regulatory agency also cited Luen Wah for releasing products to the U.S. market “without testing for total aerobic microbial count and objectionable micro-organisms.”

The letter, which was posted on the FDA’s website, followed a September 2017 inspection during which it was found that the company failed to ensure “that its drug products bore an expiration date that was supported by appropriate stability testing.”

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Luen Wah produces OTC drugs and devices for companies like Japan’s Takeda, Otsuka and Nichiban, and Germany’s Denk Pharma, according to its website. 

As a result of the inspection, the FDA placed Luen Wah on its Import Alert list in January and recommended that the company hire a consultant to help it meet CGMP standards.

The agency has recently cited three OTC drugmakers for manufacturing issues, including Luen Wah, and earlier this month posted a voluntary recall by MarcasUSA and Industria Farmacéutica Andromaco for four lots of Pasta De Lassar Andromaco Skin Protectant, an OTC skin product that was found to be contaminated after high levels of yeast, mold, and bacteria were discovered.

Suggested Articles

Pfizer's mature drugs plunged in China. AZ and GSK race their oral anemia drugs to Asia. Biotech leaders worry IP crackdown will hurt collaboration.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin.